Trebor schreef op 30 november 2021 16:45:
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Recombinant Human C1 Esterase Inhibitor (Ruconest®) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial in the United States (PROTECT-COVID-19-US)
Actual Study Start Date : November 30, 2020
Estimated Primary Completion Date : August 15, 2021
Estimated Study Completion Date : November 30, 2021
Komt er nieuws aan, vandaag loopt 30 november af.
Pharming Go Groen